GlassScriptPhysician profile
Derek W Thomson
NPI 1790917656
$14,197.23
in general payments reported to CMS, 2019-2025
60 companies · $2,241 in 2025
The $2,241 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,819 · 2020: $1,518 · 2021: $1,817 · 2022: $2,088 · 2023: $2,195 · 2024: $2,520 · 2025: $2,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,799 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,798.66 |
| Education | $156.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,143.87 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,494.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,188.76 | 2019-2025 | |
| Lilly USA, LLC | $1,002.74 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $983.63 | 2021-2025 | Ubrelvy, Vraylar, Linzess |
| Astellas Pharma US INC | $732.50 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $558.77 | 2019-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $543.15 | 2019-2025 | Jardiance, Tradjenta, Ofev |
| Janssen Pharmaceuticals, INC | $534.11 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $525.69 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $397.60 | 2019-2023 | Trintellix |
| Abbott Laboratories | $387.22 | 2021-2025 | Freestyle Libre 3 |
| Corium, LLC | $362.58 | 2021-2024 | Azstarys |
| Exact Sciences Corporation | $347.07 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $262.15 | 2019-2024 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Thomson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.